Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

NCT02980341 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

182

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Patritumab Deruxtecan

Sponsor

Daiichi Sankyo Co., Ltd.

Collaborators

[object Object]
[object Object]